The novel treatment of the medication represents a major breakthrough in the management of type 2 diabetes. Different to existing drugs, tirzepatide targets two pathways – GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) – leading to improved sugar management and possible weight reduc